IBA Launches versatile high-energy new Cyclotron

-

Thursday, June 10, 2021 - 10:40

<p>&nbsp;</p> <p><em>IBA leverages 35 years of experience and innovation in the new Cyclone<sup>®</sup> IKON with enhanced availability of theranostic radiopharmaceuticals and reduced radiopharmacy footprint<br /> &nbsp;</em><br /> <strong>Louvain-la-Neuve, Belgium, &nbsp;10 June 2021</strong> -&nbsp; <span>IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of solutions for the diagnosis and treatment of cancer, today launches its new high energy and high-capacity cyclotron, the Cyclone</span><em><sup>®</sup></em><span> IKON, which offers the largest energy spectrum for PET and SPECT isotopes from 13 MeV to 30 MeV. The Cyclone</span><em><sup>®</sup></em><span> IKON was showcased during a virtual live event and the replay can be watched <a href="https://youtu.be/LQsNCZcuwG8">here</a>.</span></p> <p><span>Currently, there are still a large number of patients for whom cancer treatment fails, despite major scientific advances. Nuclear medicine is emerging as a relevant modality to address this gap by extending overall survival and quality of life for cancer patients. Theranostics and targeted therapies allow the administration of radiation directly to the targeted cells, with minimal toxic side effects to surrounding healthy cells, unlike traditional modalities. The growing number of clinical trials (200+) and ongoing increase of new radiotherapeutic molecule developments support the great potential of radioligand therapy. &nbsp;</span></p> <p><span>“To enable this revolution, we must enhance the availability of novel isotopes and boost their production capacity. In its role, the cyclotron must be a reliable and sustainable production source of isotopes for the radiopharmaceutical industry and this is particularly the case for Germanium-68 (used for Germanium-68/Gallium-68 generators), Iodine-123 and other radioisotopes such as Copper-64, for which the demand has been consistently expanding year after year.”<strong> Bruno Scutnaire, Vice-President of IBA's RadioPharma Solutions Division commented.</strong></span></p> <p><span>To address these new market needs, IBA has redesigned its previous model, Cyclone</span><em><sup>®</sup></em><span> 30 MeV, and created a next generation system, the Cyclone</span><em><sup>®</sup></em><span> IKON. It is more compact and versatile than ever and is capable of working over a large energy span (13 to 30MeV) with full current capacity to enable the large-scale and high-purity production of emerging PET, SPECT and “parent” isotopes.&nbsp;</span></p> <p><span>The first two units of the Cyclone</span><em><sup>®</sup></em><span> IKON have already been acquired by two leading companies in radiopharmaceuticals production: The Institute of Radioelements (IRE) in Belgium and Curium Pharma in St Louis, USA. Commissioning is scheduled for 2023.</span></p> <p><span><strong>Renaud Dehareng, CEO of Curium Pharma said: </strong>“IBA has been a trusted partner of Curium for a long time. We selected IBA for its globally recognized expertise and due to the outstanding capabilities and reliability of the Cyclotron.”</span></p> <p><span>We selected IBA because of the reliability of its equipment. It has the most compact and efficient high energy cyclotron on the market." <strong>said Erich Kollegger, CEO of IRE.</strong></span><br /> &nbsp;</p> <p>&nbsp;</p> Read full press release  
Share

news.more_news_title

-

Have you already seen a flying Cyclotron?

We are proud to announce that a new Cyclone® KIUBE was rigged in Pretoria, South Africa, at Steve Biko Academic Hospital, within the framework of NuMeRI . What an achievement for the teams to hang up the cyclone on the 5th floor of the building! &nbsp; Congratulations to all involved in this project! Outstanding professionals!
Читать далее
-

IBA Reports Full Year 2022 Results

ALL-TIME RECORD ORDER INTAKE AND BACKLOG IBA ANNOUNCES MID-TERM GUIDANCE Louvain-la-Neuve, Belgium, 23 March 2023 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its consolidated results for the 2022 financial year.&nbsp; &nbsp; Financial summary All-time record annual Equipment order intake of EUR 456 million and Dosimetry order intake of EUR 67 million All-time record overall Equipment and Services backlog of EUR 1.4 billion including Equipment backlog of EUR 713 million an Services backlog of EUR 669 million Total 2022 Group revenues up 15% from 2021 to EUR 361.3 million&nbsp; Proton Therapy and Other Accelerators Services revenue increased 12.8% versus last year to EUR 135 million Gross margin was 35.1%, compared to 34.4% in 2021 Positive 2022 REBIT of EUR 11.1 million, down from EUR 14.5 million in 2021, due to the high inflationary environment, as well as increased investment into R&amp;D, infrastructure, digital technologies and sustainability to maintain IBA’s leading offering and invest in its future growth Total Group net profit of EUR 6.1 million (2021: EUR 3.9 million), positively impacted by deferred tax assets recognition related to improvement of future profitability Strong balance sheet with EUR 158 million gross and EUR 117 million net cash&nbsp; Mid-term guidance announced and dividend of EUR 0.21 per share proposed by the Board, a 10% increase from last year&nbsp; &nbsp; Business summary&nbsp; 17 new proton therapy rooms sold in 2022, compared to nine last year Other Accelerators order intake of 36 systems compared to 31 in 2021 Dosimetry order intake up 22% to a record EUR 67 million Three new installations in PT and 32 installations in Other Accelerators started during the year with four completed in PT and 20 in Other Accelerators Good progress across IBA’s four strategic sustainability streams: a) low carbon, low waste products b) low carbon, low waste company c) diverse equitable and inclusive workplace and d) accountability towards sustainability&nbsp; Olivier Legrain, Chief Executive Officer of IBA, commented: “Despite the headwinds from the global macro-economic environment, IBA has seen another strong year, driven by increasing sales across all of its business units and an all-time record order intake and backlog. On the Proton Therapy side, we have seen significant traction in Europe and the US in 2022. In addition, I’m pleased with the continued pace of deals within Industrial Solutions especially, which has continued into the start of 2023. During the year we have also been focused on future-proofing the business with targeted investments to support the Group in executing on its record backlog as well as maintaining our leading market position. With our strong backlog, good revenue visibility and high cash position, we are confident on IBA’s positive outlook for 2023 and beyond.”&nbsp; &nbsp;
Читать далее

Is PET the future of nuclear cardiology- why?

Cardiovascular diseases are the leading cause of death in the United States and worldwide. In the light of the changing landscape of cardiac diseases epidemiology, conventional imaging techniques are no longer effective for diagnosis, risk assessment, and patient management . In contrast, quantitative PET provides absolute measurements that can help tackle these challenges and significantly improve patient care.&nbsp; &nbsp; In this webinar, Dr Di Carli from Brigham and Women's Hospital and Dr. Buechel from University Hospital Zurich will explain why they believe PET imaging is the future in management of CVD.
Читать далее
-

Newsletter 29 is out!

PanTera, IBA Users Meetings, FAPI on Synthera, riggings, site acceptance test,…read it all in our autumn Newsletter !
Читать далее